Individuals who should not take semaglutide are:Those with multiple endocrine neoplasia type 2 (MEN2),medullary thyroid cancer,diabetic ketoacidosis (DKA)

Ketoconazole, a diminutive molecular compound, functions as an inhibitor of CYP51A1.

Mozart Therapeutics Showcases Preliminary Data for Key Project, MTX-101, Aimed at Autoimmune Condition Management, at the 2024 Society of Toxicology Gathering.

On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.

Madrigal Pharmaceuticals Reveals Rezdiffra™ (resmetirom) Gets Green Light from FDA to Manage Noncirrhotic NASH Sufferers with Moderate to Severe Fibrotic Liver Conditions.

Misoprostol is a small molecule drug that exerts its pharmacological effects through the activation of EP2 receptors in the body.

Zai Lab Limited plans to present early data highlighting the potential therapeutic effects of its global antibody-drug conjugate project, ZL-1310.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that plays a multifaceted role in managing type 2 diabetes and promoting weight loss.

FDA Grants Authorization for Mirum Pharmaceuticals' Drug LIVMARLI to Treat Itchy Skin Caused by Bile Buildup in Individuals with Advanced Hereditary Liver Disorder.

Atendol, a small molecule drug, falls under the ambit of the β1-adrenergic receptor antagonists class.

Almirall has entered into an exclusive licensing deal with Eloxx Pharmaceuticals for the use of ZKN-013 in the treatment of uncommon skin conditions.

Semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is a medication used for weight loss, type 2 diabetes management, and cardiovascular risk reduction.